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What’s already known about this topic? 
• Skin microscopy and Sanger sequencing are useful techniques for the accurate 
diagnosis of specific subtypes of EB.  
• The specificity and sensitivity of these current diagnostic tools is good although some 
cases of EB elude a precise laboratory diagnosis and the work involved is often time-
consuming, labour-intensive and expensive. 
• There is a need to refine and improve diagnostics for EB. 
 
What does this study add? 
• Whole-exome sequencing with bioinformatics support can identify mutations in 
cases of EB for which current diagnostic techniques fall short. 
• Whole-exome sequencing has the potential to lessen the need for diagnostic skin 
biopsies in EB, as well as reducing laboratory costs. 
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• The adoption of whole-exome sequencing into routine laboratory EB diagnostics, 
however, still requires a reduction in the time needed for both sample processing 
and data interrogation to match current diagnostic tests for EB. 
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ABSTRACT  
Background: Subtypes of inherited epidermolysis bullosa (EB) vary significantly in their 
clinical presentation and prognosis. Establishing an accurate diagnosis is important for 
genetic counselling and patient management. Current approaches in EB diagnostics involve 
skin biopsy for immunohistochemistry and transmission electron microscopy, as well as 
Sanger sequencing of candidate genes. Although informative in most cases, this approach 
can be expensive, laborious and may fail to identify pathogenic mutations in ~15% of cases.  
Objective: Next generation DNA sequencing (NGS) technologies offer a fast and efficient 
complementary diagnostic strategy, but the value of NGS in EB diagnostics has yet to be 
explored. The aim of this study was to undertake whole-exome sequencing (WES) in 9 cases 
of EB in which established diagnostic methods failed to make a genetic diagnosis.  
Methods: Whole-exome capture was performed using genomic DNA from each case of EB 
followed by massively parallel sequencing. Resulting reads were mapped to the human 
genome reference hg19. Potentially pathogenic mutations were subsequently confirmed by 
Sanger sequencing. 
Results: Analysis of WES data disclosed biallelic pathogenic mutations in each case, with all 
mutations occurring in known EB genes (LAMB3, PLEC, KIND1 and COL7A1). This study 
demonstrates that NGS can improve diagnostic sensitivity in EB compared to current 
laboratory practice.  
Conclusions: With appropriate diagnostic platforms and bioinformatics support, WES is likely 
to increase mutation detection in cases of EB and improve EB diagnostic services, although 
skin biopsy remains an important diagnostic investigation in current clinical practice.  
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 INTRODUCTION 
Epidermolysis bullosa (EB) constitutes a diverse group of genodermatoses characterized by 
trauma-induced skin fragility, blisters and erosions.
1
 Currently divided into 4 main subtypes 
(EB simplex, junctional EB, dystrophic EB and Kindler syndrome) based on the level of blister 
formation at or close to the dermal-epidermal junction (DEJ), the molecular pathology of EB 
now involves mutations in 18 genes.
1,2
 Over the last 20 years, international consensus group 
meetings have been held, most recently in 2013,
1
 to revise and update the diagnosis and 
classification of EB. New forms of EB have been added, some disease names have been 
changed, and recommendations have been made about the laboratory diagnosis of EB.
1
  
Currently, the diagnosis of most cases of EB involves a skin biopsy. Typically, skin 
sections are stained with a panel of basement membrane zone antibodies and viewed by 
immunofluorescence microscopy (IFM). In many autosomal recessive forms of EB, the 
inherent loss-of-function mutations are likely to lead to a reduction or absence of 
immunolabelling for one particular protein, thus identifying the candidate gene for Sanger 
sequencing (SS).
3-5
 In autosomal dominant forms of EB (and some autosomal recessive 
cases), however, IFM may not show clear differences from normal control skin, and further 
clues might be sought from transmission electron microscopy (TEM).
6
 The overall objective 
is to determine which gene(s) to then investigate by SS. For the known EB genes, pairs of 
primers are designed to amplify individual exons and flanking introns. Polymerase chain 
reaction (PCR) products (typically 200-350 base pairs in size) are then individually examined 
by SS. PCR amplification protocols and primer pair sequences have been published for all 
known EB genes and similar protocols and reagents have been adopted into laboratory 
practice for diagnosing EB throughout the world. Several of the EB genes contain numerous 
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exons: for example, COL7A1 (encoding type VII collagen, which is mutated in DEB) contains 
118 exons and >70 PCR primer pairs are necessary for amplification of all exons and flanking 
introns.
7,8
 To amplify all 18 genes implicated in the different forms of EB currently requires 
>400 primer pairs for genomic DNA analysis, hence the almost inevitable need for candidate 
gene clues from skin biopsies. 
In 2004, we established a national diagnostic service for EB in the UK (designated 
The Robin Eady National Diagnostic Epidermolysis Bullosa Laboratory, and based at St 
Thomas’ Hospital, London, UK). The approach to diagnosis in cases of EB has involved IFM, 
TEM and SS, as outlined above, but in a number of cases (perhaps ~15% of >1500 cases) 
these methods have failed to reveal any pathogenic mutations. Some of these cases may 
reflect erroneous clinical diagnoses by the referring clinicians but undoubtedly, technical 
limitations have also contributed to the sensitivity of current diagnostic methods.  
One new technology that could potentially improve sensitivity in EB diagnostics is 
next-generation sequencing (NGS), in which the whole genome or a portion thereof is 
sequenced.
9,10
 NGS has proven very useful for identifying novel genetic variants responsible 
for Mendelian disorders, including a new form of EBS.
11
 However, although informative in a 
research setting, the diagnostic utility of NGS remains unclear.
12-14
 To assess the potential 
impact of NGS on EB diagnostics, we undertook WES and bioinformatic data analysis on 9 
autosomal recessive cases of EB in which current diagnostic strategies had failed to identify 
one or both of the pathogenic mutations.  
 
Methodology 
Cases for study 
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The 9 cases, with a clinical diagnosis of EB, that were selected for study were all routine 
diagnostic cases referred to the National Diagnostic EB Laboratory between 2008 and 2013 
for which skin biopsy analysis and SS had failed to identify pathogenic mutations. 
 
Whole-exome sequencing 
Whole-exome capture was performed by in-solution hybridization using the SureSelect All 
Exon 50Mb Version 4.0 (Agilent) followed by massively parallel sequencing with 100-bp 
paired-end reads on the HiSeq2000 platform (Illumina).  Resulting reads were mapped to 
the human genome reference hg19 using the novoalign (Novocraft Technologies Sdn Bhd, 
Selangor, Malaysia) alignment tool. Variant calling was undertaken at the individual sample 
level with the Samtools mpileup utility.
15
 Resulting variant calls were filtered with the 
bcftools, filtered for a minimum coverage (calls with <4 reads filtered) and hard filtered for 
quality (variant with quality <20 filtered from further analysis). This high quality call set was 
then annotated with respect to the genes, and consequences on protein sequence and/or 
splicing with the Annovar tool.
16
 Further annotation regarding previously reported 
observation of specific variants and estimated population frequencies was achieved through 
further rounds of Annovar annotation against dbSNP137, population frequency estimates 
from 1000 Genomes project http://www.1000genomes.org/,  NHLBI GO Exome Sequencing 
Project (ESP) (https://esp.gs.washington.edu/drupal/), and ~1000 control exomes that have 
been processed through the same bioinformatics analysis pipeline. The exome data on all 
cases was deemed to be of very high quality. Over 8.6 gigabases of mappable sequence data 
was generated, such that >90% of the coding bases of the exome defined by the GENCODE 
Project were represented by at least 20 reads.  
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RESULTS 
 
Case 1: Generalized intermediate JEB with elusive mutation in LAMB3  
A 58-year-old white male had a clinical diagnosis of generalized intermediate JEB (previously 
known as non-Herlitz JEB)
1
 characterized by life-long trauma-induced blistering and erosions 
(illustrated on the lower limbs in Figure 1), nail loss/dystrophy and some hair loss, along 
with two separate squamous cell carcinomas. Previous skin biopsy had shown a lamina 
lucida plane of cleavage by antigen mapping and markedly reduced intensity 
immunolabelling for laminin-332. SS of LAMA3, LAMB3, LAMC2, and subsequently COL17A1, 
ITGA6 and ITGB4, however, did not reveal any mutations. By WES, we identified 236 novel 
heterozygous and 20 novel homozygous variants in his genomic DNA (see Table 1), including 
a homozygous 2-bp deletion mutation c.1587_1588delAG (p.Thr529Thrfs*6) in exon 13 of 
LAMB3, which was then verified by repeat SS. This deletion occurred within a ~4.7MB block 
of homozygosity. The mutation has been reported previously and shown to result in 
skipping of downstream exon 14,
17
 which we were also able to verify by reverse-
transcriptase PCR using RNA extracted from the patient’s skin (data not shown). Typically, 
skipping of exon 14 would be out-of-frame but with the addition of the 2-bp deletion in 
exon 13, the combined deletion is in-frame. This case shows that WES can offer a more 
sensitive approach in identifying mutations in LAMB3, but in addition, the findings question 
the current paradigm for genotype-phenotype correlation as this mutation would usually be 
expected to result in severe generalised JEB (previously referred to as Herlitz JEB).
1
 The WES 
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findings also stress the need for further studies at RNA and protein levels in some cases of 
EB.  
 
Case 2: Mild acral blistering, nail dystrophy and hypotonia with a mutation in a different 
plectin isoform  
An 18-year-old Pakistani male presented with mild blistering, developmental delay and 
hypotonia. A history of consanguinity supported autosomal recessive inheritance. IFM 
revealed a complete absence of plectin immunostaining, supporting bialleleic loss-of-
function mutations in PLEC. However, no mutation in PLEC was identified on SS. Given the 
proposed mode of inheritance and rarity of this phenotype our hypothesis was that the 
disease causing variant would be novel and homozygous. By WES we identified 454 
heterozygous and 54 homozygous novel variants (Table 1). The filtered variant list 
generated after WES included a novel frameshift mutation (c.92_93insG) in exon 1 of a 
plectin isoform previously unlinked with EB (transcript accession number: AF330791). 
Notably, only the U53204 plectin transcript is routinely sequenced during our mutation 
screening practice. We made new genomic primers to span this mutation and confirmed its 
presence on SS. The mutation identified by WES was located in a plectin isoform not 
previously thought to be expressed in skin; we have since modified our PLEC screening 
protocol accordingly.  
 
Cases 3 and 4: Kindler syndrome with elusive KIND1 mutations 
An 18-year-old Turkish male (case 3) had a history of trauma-induced blisters from early life 
with the development of some photosensitivity and poikiloderma in light-exposed sites 
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during infancy and childhood. An unrelated case, an 8-year-old Indian boy (case 4), had acral 
blistering from the first week of life, as well as photosensitivity, palmoplantar skin 
thickening, poikiloderma and a urethral stricture/stenosis. SS of KIND1 failed to reveal any 
mutations in either subject. However, in the Turkish case, WES revealed 398 novel variants 
(393 heterozygous and 5 homozygous; see Table 1), including compound heterozygous 
mutations in KIND1 (c.1811G>A, p.Trp604*; c.614G>A, p.Trp205*). The mutation p.Trp604* 
is novel, whereas p.Trp205* has been reported previously.
18
 SS of KIND1 failed to reveal any 
mutations in case 4, but WES revealed  553 novel variants (541 heterozygous and 12 
homozygous; see Table 1), which included compound known heterozygous donor splice site 
mutations, c.1718+2T>C, and c.384_385+2del4 in KIND1.
19,20
 All 4 mutations were 
confirmed in genomic DNA by repeat SS using new primers spanning the mutations. WES 
was therefore shown to be a sensitive means of identifying existing and new KIND1/FERMT1 
mutations in Kindler syndrome.  
 
Case 5: Clinically mild blistering with DST-e identified as incorrect candidate gene by IFM 
A 21-year-old white male had mild generalized skin fragility since early life: most of the 
blistering was acral. IFM showed a complete absence of immunostaining for the 230-kDa 
bullous pemphigoid antigen (BP230) but no other major differences from control skin. SS of 
DST-e (that encodes BP230), however, failed to identify any pathogenic mutations. 
Surprisingly, among 181 heterozygous and 3 homozygous novel variants identified by WES 
(Table 1), we identified compound heterozygous mutations in a different basement 
membrane zone gene, COL7A1. The mutations were c.793C>T (p.Gln265*) and c.6005G>A 
(p.Arg2002His). These mutations in COL7A1 were confirmed by SS and both parents were 
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shown to be respective carriers of one of the two mutations identified. Neither of these two 
mutations has been reported previously. Compound heterozygosity for this 
nonsense/missense combination of mutations in type VII collagen would be expected to 
lead to recessive dystrophic epidermolysis bullosa (RDEB). In this case, WES revised the 
clinical diagnosis from EBS to RDEB, although why the IFM only revealed an abnormality in      
BP230 is not known. 
 
Case 6: Missed COL7A1 mutation due to polymorphism in primer sequence  
A new-born white British male presented with generalized skin blistering in whom skin 
biopsy revealed a complete absence of type VII collagen at the DEJ, consistent with a 
diagnosis of severe generalised RDEB (Figure 2). Screening of COL7A1 by SS revealed one 
heterozygous mutation in exon 7, c.904G>T (p.Glu302*), but no second mutation. By WES, 
among 657 heterozygous and 24 homozygous novel variants (Table 1), however, a second 
mutant COL7A1 allele was identified: a heterozygous glycine substitution, c.7505G>A 
(p.Gly2502Glu), in exon 99. Neither of these mutations has been reported previously but 
both are typical of the type of gene pathology that is found in RDEB. The reason why the 
second mutation was missed by SS was because we subsequently identified a single 
nucleotide polymorphism in intron 99-100, rs6781283, which is located within the reverse 
primer used to amplify this exon and flanking introns. This polymorphism is likely to have 
prevented primer annealing and, therefore, the deleterious allele would not have been 
amplified during PCR. New primers were designed and the heterozygous glycine substitution 
was subsequently detected by SS. This finding has important implications for the optimal 
design of working primers in gene amplification and SS. 
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Cases 7-9: Elusive second allele COL7A1 mutations in RDEB 
A 27-year-old white British woman (case 7) with lifelong trauma-induced blistering and nail 
dystrophy had a clinical diagnosis of DEB, possibly localized RDEB or de novo dominant DEB, 
since no other family members were affected.  Screening of COL7A1 by SS revealed a known 
single heterozygous mutation, c.4027C>T (p.Arg1343*) in exon 34.  This finding indicated a 
diagnosis of RDEB but no second mutation was found. However, WES identified 208 
heterozygous and 9 homozygous novel variants (Table 1) that revealed a second 
heterozygous mutation, c.8676G>A (p.Trp2892*), in exon 117 of COL7A1.  This second 
mutation, which has not been reported previously, occurs close to the 3’ end of the gene 
and probably accounts for the relatively milder RDEB phenotype. 
A 26-year-old Pakistani man (case 8) had clinical features of severe generalized RDEB, 
with marked trauma-induced skin fragility, hand contractures, neck scarring, and 
oesophageal stenoses. SS of COL7A1 revealed a single previously unreported heterozygous 
mutation c.3630_3631insC (p.Gln1211Profs*8) but no identifiable second loss-of function 
mutation. However, WES disclosed 618 heterozygous and 20 homozygous novel variants 
(Table 1), including a second heterozygous mutation, c.520G>A (p.Gly174Arg) in exon 4 of 
COL7A1. This missense mutation within the NC-1 domain of type VII collagen has been 
reported previously in RDEB and shown to cause aberrant splicing. 
21
 
A 61-year-old white British woman (case 9) had lifelong mild, predominantly acral 
blistering. Two siblings were similarly affected and all were thought to have a mild form of 
RDEB. SS of COL7A1 revealed a single heterozygous mutation, c.1732C>T (p.Arg578*) in 
exon 13. 
 
The two siblings were also carriers of this mutation, which is known to be a 
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common recurrent loss-of-function mutation in COL7A1 in the UK and northern Europe.
22 
No second mutation, however, was identified by SS. In contrast, WES identified 207 novel 
heterozygous and 7 homozygous variants, including a second mutant allele, c.2126T>C 
(p.Val709Ala), in exon 16 of COL7A1, which was also present in both siblings but not in the 
exome sequences from >900 ethnically matched controls. This mutation is likely to cause 
subtle disruption to the function of type VII collagen, given the mild phenotype in this family. 
The WES data thus expand genotype-phenotype correlation by implicating a further non-
glycine missense mutation in the pathophysiology of RDEB. 
 
DISCUSSION 
In these 9 cases of EB, WES proved to be highly informative in identifying the pathogenic 
mutations. In 6 of these cases (1, 3, 4, 7, 8, 9), the mutations were missed by initial SS – not 
because of human error, but rather due to the well-known variable peak heights associated 
with current SS chemical labelling of DNA that can lead to imprecision in interpreting 
sequence traces. Review of the original sequence traces indicated either subtle changes in 
peak heights or equivocal findings, although repeat SS with close attention to the 
nucleotides implicated by WES did reveal the presence of the mutations. In case 5, it is 
uncertain why the IFM showed a lack of BP230 immunostaining when the pathogenic 
mutations were in type VII collagen – but this highlighted the potential fallibility of using IFM 
to determine the candidate gene for SS in cases of EB, even though this approach has 
proved to be highly informative, particularly in severe recessive forms of EB. In this case, the 
relatively mild clinical features were thought to be consistent with other cases that have 
demonstrated pathogenic mutations in DST-e,
23 
and thus the combination of 
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clinicopathological information unfortunately led to erroneous sequencing of DST-e. Only 
the finding of COL7A1 mutations using WES provided the true molecular pathology and 
helped correct the clinical diagnosis from autosomal recessive EB simplex to one of mild 
RDEB. For the other 2 cases, however, WES was fundamentally important in identifying the 
molecular basis of the EB. In case 2, the clinicopathological evidence pointed to plectin 
pathology but SS did not disclose any mutations in PLEC, at least using established 
sequencing protocols and primers. However, WES identified a recessive homozygous 
mutation in a different isoform of PLEC. We subsequently used reverse transcriptase PCR to 
confirm that this isoform was indeed expressed in skin (data not shown) and thereafter 
modified our PCR approach for SS of PLEC for screening future cases. In case 6, the failure of 
SS lay in the fact that there was a non-pathogenic polymorphism within one of the PCR 
primers that led to failure of amplification of that COL7A1 allele, which in this case 
happened to contain one of the pathogenic mutations. We have previously encountered 
this failure to amplify one allele for exon 23 of LAMB3 in cases of junctional EB which led to 
a redesign of the genomic DNA PCR primers,
24 
and our new findings for COL7A1 have also 
prompted us to redesign primers for exon 98 and 99 and flanking introns. The primers we 
recommend are: 5’-cgtatgtcttactccacagc (intron 97) and 5’-accctttagtcctgcactc (intron 99). 
Given that the primer pair we were using was the same as that initially suggested in a widely 
cited COL7A1 amplification protocol,
7
 our data should encourage others involved in COL7A1 
mutation analysis by SS to review their choice of PCR primers for these particular exons. 
Our study is not a direct comparison between our existing diagnostic approach for 
EB and NGS. Rather, this analysis was meant as a first step in determining whether WES 
might improve diagnostic sensitivity in EB in being able to identify mutations that have 
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proved elusive using current SS approaches. Unequivocally, WES is helpful in that regard,
25
 
although certain types of mutations may also be difficult of impossible to detect by WES, for 
example in non-coding regions.  
From a practical perspective, the introduction of NGS into routine EB diagnostics 
requires further considerations of cost, facilities, staff, and time to report. In our institution 
(King’s College London), current costs of WES (including bioinformatics analysis) are ~£900 
(2014 prices) which compares favourably with SS of EB genes. Of note, it costs a similar 
amount just to sequence the COL7A1 gene alone. Moreover, the cost of WES is likely to 
decrease further over the next few years, thus providing a strong economic argument for 
adoption of NGS into EB diagnostics. The challenge, however, lies in data interrogation and 
the bioinformatics analyses required to scrutinise the sequence variants and to determine 
causality. For EB diagnostics this would mean a realignment of technical wet lab skills (IFM 
and TEM) in favour of computer database and in silico work. The biggest challenge, however, 
lies in the time it takes to process and analyse a case. In EB diagnostics a rapid diagnosis is 
often very important to optimise clinical management, particularly in neonates with fragile 
skin. The current approach using skin biopsy assessment followed by SS of candidate genes 
(implicated by IFM and/or TEM) allows for possible diagnoses to be made within 2-3 days. In 
contrast, the quickest time that WES could be completed (at present) would be a minimum 
of 5 days. Being able to reduce the time it takes to make a diagnosis using WES, therefore, 
will be fundamental to its application in clinical service. New platforms to enable this are in 
development, but only when more rapid sample analysis is feasible in a diagnostic lab 
setting can one really begin to think about changing diagnostic practice. For now, however, 
skin biopsy remains an integral part of current EB diagnostics.  
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Table 1. WES data and impact on EB diagnostics for the 9 cases studied. 
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Patient no. Clinical diagnosisGene Mutation Mutation typePolyPhen-2: prediction, scoreSIFT: prediction, score Inheritance Heterozygous Homozygous Impact of WES
Case 1 GIJEB LAMB3 c.1587_1588del2,PTC Frameshift AR Identification of an atypical mutation in LAMB3  with implications for revising genotype-phenotype correlation.
236 20
Case 2 EBS PLEC c.92_93insG, PTC Frameshift AR Identification of a PLEC  mutation in an isoform not thought to be expressed in skin with implications for expanding 
454 54 PLEC gene screening for diagnostic practice
Case 3 Kindler KIND1/FERMT1c.1811G>A, p.Trp604* Nonsense AR Improved detection of KIND1/FERMT1  mutations indicating current SS primers are sub-optimal
c.614G>A, p.Trp205* Nonsense 393 5
Case 4 Kindler KIND1/FERMT1c.1718+2T>C Splice site AR Improved detection of KIND1/FERMT1  mutations indicating current SS primers are sub-optimal
c.384_385+2del4 Splice site 541 12
Case 5 EBS/RDEB COL7A1 c.793C>T, p.Gln265* Nonsense AR Identification of mutations in a different, unsuspected EB gene providing a diagnosis that would otherwise have been
c.6005G>A, p.Arg2002HisMissense Probably damaging, 1 Tolerated, 0.11 181 3  clinically erroneous and missed in SS screening
Case 6 severe RDEB COL7A1 c.904G>T, p.Glu302* Nonsense AR Improved detection of COL7A1  mutations in exon 98 and 99 because of previous failure to amplify DNA due to a 
c.7505G>A, p.Gly2502GluMissense Probably damaging, 0.999 Damaging, 0 657 24 polymorphism within one of the PCR primers used for SS
Case 7 mild RDEB COL7A1 c.4027C>T, p.Arg1343* Nonsense AR Improved detection of COL7A1  mutations indicating current SS primers are sub-optimal
c.8676G>A, p.Trp2892* Nonsense 208 9
Case 8 severe RDEB COL7A1 c.3630_3631insC, PTC Frameshift AR Improved detection of COL7A1  mutations indicating current SS primers are sub-optimal
c.520G>A, p.Gly174Arg Missense Probably damaging, 1 Damaging, 0.002 618 20
Case 9 mild RDEB COL7A1 c.1732C>T, p.Arg578* Nonsense AR Improved detection of COL7A1  mutations indicating current SS primers are sub-optimal
c.2126T>C, p.Val709Ala Missense Possibly damaging, 0.939 Damaging, 0 207 7
GIJEB:generalised intermediate junctional epidermolysis bullosa; EBS: Epidermolysis bullosa simplex; RDEB: recessive dystrophic epidermolysis bullosa; SS: Sanger Sequencing; PTC: premature termination codon; WES: Whole Exome Sequencing; AR: autosomal recessive.
24250
638
24231
214
24001
681
24260
217
24283
553
23649
184
24257
508
24504
398
Single nucleotide substitutions in WES (number)
Novel
256
Known
23488
Page 20 of 20British Journal of Dermatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
